EcoDrugPlus

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSCGOG00000013292
Gene Symbol: PSMA6
3 Cross references
229 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSCGOG00000023801
Gene Symbol: PSMA8
3 Cross references
183 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSCGOG00000020593
Gene Symbol: PSMB1
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSCGOG00000008253
Gene Symbol: PSMB2
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSCGOG00000012333
Gene Symbol: PSMB3
3 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSCGOG00000003748
Gene Symbol: PSMB4
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSCGOG00000012929
Gene Symbol: PSMB8
3 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSCGOG00000012765
Gene Symbol: PSMB9
3 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSCGOG00000015513
Gene Symbol: PSMC1
3 Cross references
318 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSCGOG00000006423
Gene Symbol: PSMC2
3 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSCGOG00000020650
Gene Symbol: PSMC3
3 Cross references
227 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSCGOG00000001683
Gene Symbol: PSMC4
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).